Long-term remission in multiple myeloma—a blood cancer once considered incurable—is finally becoming a reality. A single ...

Iberdomide combined with standard therapies showed a statistically significant improvement in minimal residual disease (MRD) ...

Regeneron unveiled what it calls "paradigm-shifting" test results for a drug that could prevent patients from developing multiple myeloma.

As many as one third of newly diagnosed multiple myeloma (MM) cases are classified as high risk, with widely varying rates of ...

Recent studies highlight the potential of minimal residual disease (MRD) testing to influence treatment decisions in multiple myeloma and chronic lymphocytic leukemia. Testing for minimal residual ...

Boston, MA — Researchers at Dana-Farber Cancer Institute have developed a blood test that could transform the diagnosis and monitoring of multiple myeloma (MM) and its precursor conditions. The new ...

Are an adult with relapsed or refractory multiple myeloma Have tried at least four previous lines of treatments for multiple myeloma, including: Immune system modulators (help boost the immune system ...

Birmingham researchers have received £230k of translational funding from Cancer Research Horizons to develop a prototype for a new test to monitor people at risk of developing the blood cancer ...

A woman experienced migraines. Doctors did not address her condition. She later showed stroke symptoms. Hospital tests ...

Nearly everyone with multiple myeloma relapses. That doesn’t make it easy. A cancer diagnosis is traumatic, especially when the cancer is treatable, but not curable. In multiple myeloma, the disease ...

Medically reviewed by Doru Paul, MD Your survival rate for multiple myeloma is likely higher in earlier stages. Younger people often have better outcomes due to their resilience to intensive ...